Liver/Biliary Disorders News

Testing for HIV, hepatitis B, and hepatitis C increased among U.S. Medicaid enrollees initiating treatment for opioid use disorder. However, a recent study showed approximately three-quarters of enrollees were not tested for each condition.

WASHINGTON — Active IV or prescription drug use did not affect attainment of sustained virologic response when treatment adherence for hepatitis C virus was already variable, according to a poster presented at The Liver Meeting.

Roux-en-Y gastric bypass was associated with an increased risk for alcohol-use disorder-related hospitalization compared with sleeve gastrectomy and a weight management program, according to research published in JAMA Surgery.

Robotic liver resection for hepatocellular carcinoma yielded better perioperative tolerability and may be a safe and effective alternative to open liver resection, according to research published in JAMA Surgery.

Since April 2022, more than 1,300 children in 35 countries have developed acute severe hepatitis of unknown etiology, with the United States and the United Kingdom accounting for 65% of global cases, according to recent WHO data.

Blood endotoxin levels were increased among patients with nonalcoholic fatty liver disease compared with healthy controls and may serve as a relevant diagnostic biomarker, according to research in Clinical Gastroenterology and Hepatology.

Abstinence from alcohol was associated with reduced risk for hepatic decompensation and mortality among patients with alcohol-related cirrhosis, regardless of disease stage, according to results in Clinical Gastroenterology and Hepatology.

Topline findings from the phase 3 MAESTRO-NASH trial showed that resmetirom at both 100 mg and 80 mg doses improved resolution of nonalcoholic steatohepatitis without worsening fibrosis, Madrigal Pharmaceuticals announced.

Less than two-thirds of insured patients with viremic hepatitis C virus infection received treatment with direct-acting antivirals from 2014 to 2021, with a sharp decline in diagnoses and treatment reported during the COVID-19 pandemic.

Mirum Pharmaceuticals announced the European Commission has approved Livmarli for the treatment of cholestatic pruritis in patients with Alagille syndrome.